Bioinvent International AB
Research Bioinvent International AB (0H22) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- Ticker0H22
- ExchangeLSE
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
About Bioinvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors;
Frequently asked questions
What does Bioinvent International AB do?
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally.